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Abstract 
Introduction: Post-transplant diabetes mellitus (PTDM), pre-diabetes-impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG) are frequent complications after organ transplantation. The aim of this study was to assess the frequency of PTDM, IFG and IGT in 
a group of renal transplant recipients, to compare the frequency of glucose metabolism disorders in subjects treated with tacrolimus and 
with cyclosporine, and to establish the influence of different risk factors on the development of glucose metabolism disorders. 
Material and methods: We examined 206 non-diabetic kidney allograft recipients (age 46.4 ± 12.3 years, time since transplantation 45.5 ± 
± 33.6 months, BMI 26.3 ± 4.5 kg/m2). Glucose metabolism disorders were diagnosed using an oral glucose tolerance test. Logistic regres-
sion was used to assess the influence of each risk factor (age, BMI, waist circumference, physical activity, the presence of cardiovascular 
disease, positive family history of diabetes, cholesterol and triglycerides concentration) on the development of glucose metabolism disorders. 
Results: In 103 patients (50%), we diagnosed glucose metabolism disorders. 19% of patients had PTDM, 14% IFG, and 17% IGT. We did 
not find any differences in the frequency of glucose metabolism disorders between patients treated with tacrolimus and with cyclosporine. 
Multivariate analysis identified BMI and a family history of diabetes as independent risk factors of glucose metabolism disorders. 
Conclusions: We found a high prevalence of glucose metabolism disorders in the examined group. This suggests that kidney transplant 
recipients should be screened for these disturbances. Patients with higher BMI and with first-degree relatives with diabetes had an increased 
risk of glucose metabolism disorders after kidney transplantation. (Endokrynol Pol 2013; 64 (1): 21–25)
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Streszczenie
Wstęp: Cukrzyca potransplantacyjna (PTDM) jak również stan przedcukrzycowy — nieprawidłowa glikemia na czczo (IFG) i nieprawidłowa 
tolerancja glukozy (IGT) są jednymi z częstszych powikłań po przeszczepieniu narządu. Celem pracy była ocena częstości występowania 
PTDM, IFG i IGT u osób po przeszczepieniu nerki, porównanie częstości występowania zaburzeń gospodarki węglowodanowej u osób 
leczonych takrolimusem i cyklosporyną oraz ocena wpływu różnych czynników ryzyka na rozwój tych zaburzeń.
Materiał i metody: W badaniu wzięło udział 206 osób po przeszczepieniu nerki bez rozpoznanych dotychczas zaburzeń gospodarki 
węglowodanowej (wiek 46,4 ± 12,3 lat, czas od przeszczepienia 45,5 ± 33,6 miesięcy, BMI 26,3 ± 4,5 kg/m2). U wszystkich badanych wy-
konano test doustnego obciążenia glukozą. W celu oceny wpływu poszczególnych czynników ryzyka (wiek, BMI, obwód talii, aktywność 
fizyczna, obecność choroby sercowo-naczyniowej, dodatni wywiad rodzinny w kierunku cukrzycy, stężenie cholesterolu i triglicerydów) 
na rozwój zaburzeń gospodarki węglowodanowej wykorzystano model regresji logistycznej. 
Wyniki: U 103 pacjentów (50%) zostały rozpoznane zaburzenia gospodarki węglowodanowej. U 19% badanych zdiagnozowano PTDM, 
u 14% IFG, u 17% IGT. Nie stwierdzono różnic w częstości występowania zaburzeń gospodarki węglowodanowej u leczonych takrolimu-
sem w porównaniu z leczonymi cyklosporyną. W analizie wieloczynnikowej tylko BMI i dodatni wywiad rodzinny w kierunku cukrzycy 
okazały się niezależnymi czynnikami ryzyka zaburzeń gospodarki węglowodanowej. 
Wnioski: W badanej przez nas grupie chorych stwierdziliśmy wysoką częstość występowania zaburzeń gospodarki węglowodanowej. 
Wskazuje to na potrzebę prowadzenia badań przesiewowych w tym kierunku u osób po przeszczepieniu nerki. Osoby z wyższym BMI 
i z rodzinnym obciążeniem cukrzycą mają podwyższone ryzyko rozwoju zaburzeń gospodarki węglowodanowej po przeszczepieniu 
nerki. (Endokrynol Pol 2013; 64 (1): 21–25)
Słowa kluczowe: cukrzyca potransplantacyjna, czynniki ryzyka, przeszczepienie nerki
Introduction
Post-transplant diabetes mellitus (PTDM), pre-diabetes-
impaired glucose tolerance (IGT) and impaired fasting 
glucose (IFG) are the most frequent complications 
after renal transplantation. PTDM is associated with 
higher costs of post-transplant care and increased risk 
of graft rejection, infection, cardiovascular disease and 
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death. In PTDM, as in type 2 diabetes, two defects 
coexist — insulin resistance and impaired β-cell func-
tion. The pathogenesis of PTDM is multifactorial and 
constitutes a combination of traditional risk factors 
typical for diabetes type 2 plus specific factors such as 
pre-existing chronic kidney disease, exposure to im-
munosuppressive drugs such as corticosteroids and 
calcineurin inhibitors — tacrolimus and cyclosporine 
[1–3]. The importance of different risk factors on the 
development of glucose metabolism disorders after 
renal transplantation is not well established. 
The aim of this study was to assess the frequency 
of PTDM, IFG and IGT in a group of renal transplant 
recipients, to compare the frequency of glucose metabo-
lism disorders in subjects treated with tacrolimus and 
treated with cyclosporine, and to establish the influence 
of different risk factors on the development of glucose 
metabolism disorders. 
Material and methods
During routine visits in the hospital outpatient trans-
plantology clinic we examined 206 patients (80 women 
and 126 men), with no history of earlier glucose me-
tabolism disorders (normal concentration of fasting 
and postprandial plasma glucose), who had had renal 
transplantation between 2000 and 2006. Age and the 
time since renal transplantation were recorded. 
Weight, height and waist circumference were 
measured. Body mass index (BMI) was calculated. 
Information about coexisting cardiovascular diseases 
(hypertension, ischaemic heart disease, heart failure, 
cerebrovascular disease, atherosclerosis of lower ex-
tremities’ arteries), family history of diabetes (the pres-
ence of type 2 diabetes in parents or siblings) and the 
level of physical activity (low — a sedentary lifestyle, 
high — physical exercise lasting more than one hour 
three times a week, and moderate — between ‘low’ and 
‘high’) was also obtained. The scheme of immunosup-
pressive regimen was analysed. Plasma cyclosporine 
and tacrolimus concentrations were determined 
12 hours after administration of the drug. Serum triglyc-
erides and cholesterol concentrations were estimated.
Glucose metabolism disorders were diagnosed 
on the basis of an oral glucose tolerance test (OGTT) 
according to the ADA/WHO criteria [4]. IFG was 
diagnosed when fasting plasma glucose level was 
≥ 100 mg/dL and ≤ 125 mg/dL. IGT was diagnosed if 
plasma glucose two hours after administration of 75 g 
of glucose was ≥ 140 and ≤ 199 mg/dL. Diabetes was 
diagnosed if fasting plasma glucose was ≥ 126 mg/dL 
(confirmed twice) or glucose in the second hour of 
OGTT was ≥ 200 mg/dL [2]. 
The characteristics of the examined group are set 
out in Table I. 
A total of 57 (28%) subjects suffered from at least one 
cardiovascular disease. In 32 patients (16%), we found a 
positive family history of type 2 diabetes. Low, moderate 
and high levels of physical activity were declared by 
44 (25%), 97 (54%) and 37 (21%) subjects, respectively. 
All patients had been receiving immunosuppressive 
therapy according to the scheme: prednisone (n = 206), 
Table I. Characteristics of the examined patients
Tabela I. Charakterystyka badanej grupy 
Parameter Mean SD Minimum Maximum
Age (years) 46.4 12.3 19 72
Time since transplantation (months) 45.5 33.6 1 182
Weight [kg] 74.9 13.0 45 111
Height [m] 1.7 0.09 1.5 2.0
BMI [kg/m2] 26.3 4.5 16.3 39.1
Waist circumference — women [cm] 85.2 13.6 45 114
Waist circumference — men [cm] 93.5 11.0 67 130
Systolic blood pressure [mm Hg] 132 14.3 90 180
Diastolic blood pressure [mm Hg] 82 8.0 60 110
Total cholesterol [mg/dL] 213 44.2 124 460
Triglycerides [mg/dL] 163 85.3 53 577
Cyclosporine dose [mg] 226 72.2 100 600
Tacrolimus dose [mg] 5.5 2.9 2.0 13.0
Prednisone dose [mg] 8.3 3.0 2.5 20.0
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calcineurin inhibitor (tacrolimus (n = 65) or cyclosporine 
(n = 141)) and antiproliferative drug (azathioprine or 
mycophenolate mofetil). The characteristics of the group 
of patients treated with tacrolimus compared to the 
group treated with cyclosporine are set out in Table II. 
Data is expressed as means ± SD. The comparisons 
between the two groups (one treated with tacroli-
mus and the other treated with cyclosporine) were 
performed by z-test or Student’s t-test, or by non-
parametric U Mann Whitney test if the data was not 
normally distributed. Multiple logistic regression was 
used to assess the influence of each risk factor (age, 
BMI, waist circumference, physical activity, the pres-
ence of cardiovascular disease, positive family history 
of diabetes, cholesterol and triglycerides concentration) 
on the development of glucose metabolism disorders. 
Results were considered statistically significant where 
p < 0.05. Data analysis was made using Statistica® 2000 
for Windows. 
The study was approved by the Ethics Committee for 
Medical Research, Collegium Medicum in Bydgoszcz, and 
is in accordance with the Helsinki Declaration. Informed 
consent was given by all patients participating in the study. 
Results
In 50% of examined patients after kidney transplan-
tation, we found glucose metabolism disorders. The 
distributions of normal glucose tolerance, IGT, IFG and 
PTDM in the examined group are shown in Figure 1.
In the group treated with tacrolimus, 23 patients 
(15%) had PTDM, 11 (17%) had IFG, and seven (11%) 
had IGT. In the group treated with cyclosporine, we 
found PTDM in 18 (25%) patients, IFG in 17 (12%), 
and IGT in 28 (20%). The differences in the frequency 
of these disorders between the two groups were not 
statistically significant. 
Tacrolimus concentration was significantly higher 
in patients with glucose metabolism disorders than in 
patients with normoglycaemia (10.32 v. 8.63 ng/mL; p 
< 0.01). Cyclosporine level did not differ between pa-
tients with and without glucose metabolism impairment 
(163.1 v. 149.9 ng/mL; p = 0.09). 
In logistic regression, six risk factors of diabetes, 
i.e. the presence of cardiovascular disease (p = 0.7), 
cholesterol concentration (p = 0.41), triglycerides 
concentration (p = 0.29), waist circumference (p = 0.24), 
age (p = 0.16) and physical activity (p = 0.1) did not 
influence significantly the occurrence of glucose me-
tabolism disorders. Only positive family history of 
diabetes (regression factor = 1.023; p = 0.028951) and 
BMI (regression factor = 0.142; p = 0.0016) were inde-
pendent risk factors. 
Discussion
The prevalence of PTDM has been previously widely 
studied, but the frequency of prediabetes in kidney 
transplant recipients has not been sufficiently examined. 
In this study, we used OGTT as the most reliable method 
in the screening of diabetes and as the sole method of 
Table II. Characteristics of the group of patients treated with tacrolimus compared to the group treated with cyclosporine
Tabela II. Charakterystyka pacjentów leczonych takrolimusem w porównaniu z pacjentami leczonymi cyklosporyną
Parameter Group treated with tacrolimus  
(n = 65)
Group treated with cyclosporine 
(n = 141)
p
Number/percentage of women [n /%] 23/45 57/40 p = 0.69
Number/percentage of men [n/%] 42/65 84/60
Age (years) 42.1 ± 11.7 48.6 ± 11.9 p < 0.001
BMI [kg/m2] 25.64 ± 3.58 26.39 ± 4.67 p = 0.27
Figure 1. Distribution of normal glucose tolerance (NGT), 
impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG) and post-transplant diabetes mellitus (PTDM) in the 
examined group
Rycina 1. Częstość występowania prawidłowej tolerancji glukozy 
(NGT), nieprawidłowej tolerancji glukozy (IGT), nieprawidłowej 
glikemii na czczo (IFG) i cukrzycy potransplantacyjnej (PTDM) 
w badanej grupie chorych
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diagnosing IFG and IGT. We found a high prevalence 
(50%) of glucose metabolism disorders in the examined 
group of patients. The incidence rates of PTDM vary by 
organ transplanted and by post-transplant interval. In 
the first year after transplantation, 20-50% of kidney 
transplant recipients develop PTDM [3]. In our study, 
the incidence of PTDM was 19%, which is similar to 
that reported by other authors [1, 5, 6]. The frequency 
of IFG and IGT was also high — 14% and 17%, respec-
tively. Mathew found IGT in 24.1% according to OGTT 
results performed six months after transplantation [1]. 
In a French study, IFG was found in 7.9% of patients 
after kidney transplantation, but this condition was 
diagnosed only on the basis of fasting blood glucose 
concentration according to a previous ADA/WHO 
definition (fasting glucose between 110 and 125 mg/ 
/dL) [7]. Patients with prediabetes are at increased risk 
of cardiovascular events. About 7% of them progress to 
diabetes every year. They require therapeutic interven-
tions to prevent the progression to overt diabetes [8]. 
Therefore, in our study further analyses were made in 
the whole group of patients with glucose metabolism 
disorders — with PTDM, as well as IFG and IGT. 
The use of immunosuppressive drugs such as 
corticosteroids and calcineurin inhibitors after renal 
transplantation affects the carbohydrate metabolism. 
Tacrolimus-based regimens are associated with more 
profound beta-cell morphological changes and in-
hibition of insulin secretion to a greater extent than 
cyclosporine-based regimens [9]. Clinical studies have 
confirmed that tacrolimus exerts a stronger diabetogenic 
effect than cyclosporine [5, 10]. This effect of tacrolimus 
is dose-dependent [11]. We also found a higher tacroli-
mus concentration in patients with glucose metabolism 
disorders than in patients with normoglycaemia. We did 
not reveal any significant differences in the frequency of 
glucose metabolism disorders between the group receiv-
ing tacrolimus and the group receiving cyclosporine. 
However, patients treated with cyclosporine were older 
than subjects treated with tacrolimus. The incidence of 
glucose metabolism disorders increases with age and 
this may explain the similar frequency of PTDM, IFG 
and IGT in both groups: younger, treated with poten-
tially stronger diabetogenic drug (tacrolimus) and older, 
treated with cyclosporine. The different characteristics 
of both groups do not allow us to draw conclusions 
about the influence of the type of calcineurin inhibitor 
on glucose metabolism. 
In our study, logistic regression revealed two inde-
pendent risk factors of glucose metabolism disorders 
after renal transplantation: BMI and positive family 
history of type 2 diabetes mellitus. 
Obesity is one of the strongest risk factors for diabe-
tes type 2. The results of several studies have confirmed 
that obesity at transplantation is an independent risk 
factor also for PTDM [5, 10, 12–18]. Gonzales-Posada in 
a group of 3,365 renal transplant recipients showed that 
the risk of PTDM increases in patients with overweight 
(BMI > 25 kg/m2), and becomes apparent in obese sub-
jects (BMI > 30 kg/m2) [19]. Maximum lifetime body 
mass index > 25 kg/m2 was found to be a risk factor for 
PTDM in the study by Kamar [7]. 
The strong familial clustering of diabetes emphasises 
the important role of genetic factors in the pathogenesis 
of type 2 diabetes: 15–25% of first-degree relatives of 
patients with type 2 diabetes develop impaired glucose 
tolerance or diabetes [20]. In most papers assessing dif-
ferent risk factors of PTDM, data regarding family his-
tory of diabetes has not been collected [1, 5, 10, 12–14]. 
In the study by Kamar, 27% of patients had at least one 
family member with diabetes, and a first-degree relation 
was found in 66% of them. In this study, a family his-
tory of diabetes did not correlate with the development 
of PTDM [7]. Similarly in the group of cyclosporine-
treated renal transplant recipients, a family history 
of diabetes was not associated with PTDM [21]. Also, 
Sulanc did not find any relationship between a family 
history of diabetes and the risk of development of new-
onset diabetes after kidney transplantation [22]. In our 
study, the presence of diabetes in first-degree relatives 
was an independent risk factor of glucose metabolism 
disorders after kidney transplantation. Marin et al. also 
found a significant correlation between a family history 
of diabetes and the onset of PTDM, diagnosed on the 
basis of fasting glucose concentrations [15]. Similarly, 
a positive family history of diabetes was an independent 
predictor of new-onset post-transplant diabetes mellitus 
in the study by Madziarska [23]. 
Our study has some limitations. Its cross-sectional, 
not prospective, design is one of them. Other limitations 
are the large differences in the time since transplanta-
tion (high SD value), and the different, non-comparable, 
characteristics of patients treated with tacrolimus and 
cyclosporine. 
On the other hand, we assessed different traditional 
risk factors, including family history of diabetes, the 
presence of cardiovascular disease, and the level of 
physical activity. These factors are often ignored in 
studies evaluating the risk of PTDM in kidney trans-
plant recipients. In contrast to most previous studies, 
we diagnosed PTDM and prediabetes using OGTT and 
according to current ADA/WHO criteria. 
Conclusions
We found a high prevalence of glucose metabolism 
disorders in the examined group of kidney transplant 
recipients. Our results showed that patients with higher 
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BMI and with first-degree relatives with diabetes had 
an increased risk of developing glucose metabolism 
disorders after kidney transplantation. They should 
be screened for these disturbances. A positive family 
history of diabetes is not a modifiable risk factor. Over-
weight and obesity, potentially modifiable risk factors, 
are difficult to modify in clinical practice. Lifestyle 
modification should be applied to decrease weight and 
to reduce the risk of PTDM and prediabetes. Another 
preventative strategy is the selection of a potentially less 
diabetogenic immunosuppressive regimen in patients 
at high risk of glucose metabolism disorders.
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